QIAGEN acquires N-of-One, expanding its clinical bioinformatics capabilities in molecular oncology decision support

  • Posted by Emily Haynes
  • On January 7, 2019
  • 0 Comments
Enhancing QIAGEN’s industry-leading position with access to MarkerMine™ database and real-world evidence insights that provide insights for targeted therapy options Redwood City, California, and Hilden, Germany, January 7, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today it has entered into an agreement to acquire N-of-One, Inc., a privately-held U.S. molecular decision […]
Read More

N-of-One to Incorporate New AMP Guidelines on Somatic Cancer Variants into its Best-in-Class Curation and Reporting for Patient-Specific Oncology Decision Support

  • Posted by Emily Haynes
  • On September 20, 2017
  • 0 Comments
September 20, 2017, Concord, MA – N-of-One, Inc., the leader in clinical interpretation of molecular tests in oncology, is proud to announce the incorporation of the recent AMP guidelines on reporting somatic cancer variants with enhanced levels of evidence (LOE) into N-of-One’s existing curation and reporting. In December of 2016, to address the field’s need […]
Read More

N-of-One, Inc Announces New Vice President of Business Development

  • Posted by Emily Haynes
  • On April 26, 2017
  • 0 Comments
Rich Gray to lead N-of-One’s business development team in strategy focused on channel partner sales Concord, Mass. April 26, 2017 – N-of-One, Inc., the leader in clinical interpretation of molecular tests in oncology, announced that Rich Gray has joined their team as the new Vice President of Business Development. Rich will leverage his 25+ years […]
Read More

N-of-One® dramatically speeds high-accuracy interpretation of the Illumina TrueSight Tumor170 Cancer Panel

  • Posted by Emily Haynes
  • On February 21, 2017
  • 0 Comments
Concord, Mass. February 21, 2017 – N-of-One, Inc., founded in 2008 as a leader in interpretation of molecular tests in oncology, announced today the launch of RapidInsights for Illumina’s TruSight Tumor 170 (TST170). RapidInsights is a fully automated interpretation solution that, in a matter of minutes, will read the bioinformatics output of the genomic variants […]
Read More

Philips teams up with Molecular decision support leader N-of-One to speed up clinical interpretation of cancer genomics

  • Posted by Emily Haynes
  • On November 11, 2016
  • 0 Comments
Alliance aims to fortify precision medicine oncology decision support for clinicians Philips IntelliSpace Genomics solution leverages N-of-One’s extensive and variant database and interpretation solutions to extend the reach and scale of personalized medicine Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, and N-of-One, Inc., the leader in […]
Read More

med fusion Selects N-of-One to Provide Integrated Interpretation for med fusion’s New Hematologic Neoplasm Profiles

  • Posted by Emily Haynes
  • On November 8, 2016
  • 0 Comments
CONCORD, Mass., November 8, 2016 – N-of-One, Inc., a market leader in clinical interpretation with clinical trial matching for molecular tests, today announced that med fusion, a Texas Oncology and The US Oncology Network preferred laboratory, has selected N-of-One to provide integrated interpretation of med fusion’s new HemeSEQ™ profiles for AML, CLL, DLBCL and MPN diseases. MDS […]
Read More

Inivata and N-of-One Partner to Provide Personalized Genomic Interpretation and Clinical Trial Matching for Cancer Patients

  • Posted by Emily Haynes
  • On November 3, 2016
  • 0 Comments
N-of-One to Identify Treatment Strategies and Clinical Trial Opportunities for Patients based on Inivata’s ctDNA Liquid Biopsy Analysis Research Triangle Park, NC/Cambridge, England and Concord, Mass., November 3, 2016 – Inivata, a global clinical cancer genomics company employing a revolutionary approach to circulating tumor DNA (ctDNA) analysis to improve personalized healthcare in oncology, and N-of-One, […]
Read More

Inova Schar Cancer Institute Partners with N-of-One to Support the Launch of Inova’s Molecular Tumor Board

  • Posted by Emily Haynes
  • On October 12, 2016
  • 0 Comments
N-of-One’s Clinical Interpretation and Clinical Trial Matching Provides Patient-Specific Treatment Strategies to Empower Inova’s Precision Medicine Program CONCORD, Mass., Oct. 12, 2016 – N-of-One, Inc., a precision medicine oncology decision support company, today announced a partnership with Inova Schar Cancer Institute (ISCI) to support its molecular tumor board, the first in the DC metro area to invite […]
Read More

N-of-One Secures $7 Million in Series B Financing to Expand its Leading Precision Medicine Oncology Decision Support Solutions

  • Posted by Emily Haynes
  • On July 21, 2016
  • 0 Comments
LEXINGTON, Mass. (July 21, 2016)—N-of-One, a precision medicine oncology decision support company, announced today that it has received $7 million in a Series B financing from Providence Ventures and Excel Venture Management. The financing will be used to expand the company’s R&D efforts to broaden its precision medicine clinical decision support solutions in oncology, providing […]
Read More

N-of-One Selected by Admera Health to Provide Clinical Interpretation for the OncoGxOne™ 64-Gene Oncology Panel

  • Posted by Emily Haynes
  • On April 12, 2016
  • 0 Comments
LEXINGTON, Mass., April 12, 2016 – N-of-One, Inc., the leader in clinical interpretation of molecular tests in oncology, today announced that Admera Health, a molecular diagnostics company focused on personalized medicine and non-invasive cancer testing, has selected N-of-One to provide clinical interpretation of their 64-gene oncology panel, OncoGxOne™. N-of-One’s patient-specific analysis is based on the clinical and […]
Read More
BACK TO
TOP
LEARN
MORE